Aztreonam-amoxicillin/clavulanate combination therapy against bla NDM-producing Enterobacterales infections
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf379 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Efrat Orenbuch-Harroch und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel. Hauptthemen laut MEDLINE: Aztreonam, Enterobacteriaceae Infections, Anti-Bacterial Agents, beta-Lactamases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
Aztreonam plus ceftazidime/avibactam is recommended against NDM-producing Enterobacterales. Pairing with clavulanate can also restore aztreonam’s activity.
Objectives
To report on the clinical experience with antimicrobial susceptibility testing–guided aztreonam therapy combined with β-lactamase inhibitors, particularly amoxicillin-clavulanate, against NDM-producing Enterobacterales infections.
Methods
All patients with infections caused by NDM-producing Enterobacterales that were resistant to aztreonam monotherapy but demonstrated in vitro synergy and thus eligible for aztreonam combination therapy, who received ≥5 days of aztreonam-based combination therapy, were included. Gradient strip-crossing methodology was validated against broth microdilution for susceptibility testing. Clinical response was assessed at 30 days post-treatment.
Results
Clinical cure was achieved in 78% (7/9) of aztreonam/amoxicillin-clavulanate patients and 56% (9/16) of aztreonam/ceftazidime-avibactam patients. Treatment duration averaged 11.8 and 11.6 days, respectively. Among 21 sequenced isolates, blaNDM-1 was most prevalent. In vitro synergy was demonstrated in 52% with clavulanate and 90% of isolates with avibactam. Gradient strip-crossing showed 80% essential agreement and 100% categorical agreement for both combinations. Transient hepatic enzyme elevations occurred in three liver transplant recipients.
Conclusions
Our findings suggest aztreonam/amoxicillin-clavulanate combination therapy guided by gradient strip-crossing as a potential broad-spectrum-sparing strategy for selected patients with NDM-producing Enterobacterales infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
- Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
- Faculty of Medicine, Hebrew University, Jerusalem, Israel.
ORCID-Profile: Yonatan Oster, Daniel Grupel, Jacob Strahilevitz
Zitieren
APA
Orenbuch-Harroch, E., Snoyman, G., Nashashibi, M. A., Temper, V., Oster, Y., Grupel, D., Reshef, D., Moran-Gilad, J., & Strahilevitz, J. (2025). Aztreonam-amoxicillin/clavulanate combination therapy against bla NDM-producing Enterobacterales infections. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf379
Vancouver
Orenbuch-Harroch E, Snoyman G, Nashashibi MA, Temper V, Oster Y, Grupel D, et al. Aztreonam-amoxicillin/clavulanate combination therapy against bla NDM-producing Enterobacterales infections. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf379
BibTeX
@article{OrenbuchHarroch2025,
author = {Orenbuch-Harroch, Efrat and Snoyman, Gabriella and Nashashibi, Munther Aqeel and Temper, Violeta and Oster, Yonatan and Grupel, Daniel and Reshef, Dan and Moran-Gilad, Jacob and Strahilevitz, Jacob},
title = {Aztreonam-amoxicillin/clavulanate combination therapy against bla NDM-producing Enterobacterales infections},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf379}
}
EUVIMED